Please use this identifier to cite or link to this item:
Title: Role and New Insights of Pirfenidone in Fibrotic Diseases
Authors: Lopez de la Mora, David Alejandro
Sánchez Roque, Cibeles
Montoya Buelna, Margarita
Sánchez Enríquez, Sergio
Lucano Landeros, Silvia
Macias Barragan, José
Armendáriz Borunda, Juan Socorro
Keywords: pirfenidone
idiopathic pulmonary fibrosis
Issue Date: 2015
Publisher: Ivyspring International Publisher
Citation: López de la Mora D.A., Sanchez Roque C., Montoya Buelna M., Sánchez Enríquez S., Lucano Landeros S., Macías Barragán J. y Armendariz Borunda J. (2015). Role and New Insights of Pirfenidone in Fibrotic Diseases. International Journal of Medical Sciences. Vol. 12, núm. 11
Series/Report no.: International Journal of Medical Sciences.;Vol. 12, núm. 11
Abstract: Pirfenidone (PFD) is a non-peptide synthetic molecule issued as a broad-spectrum anti-fibrotic drug with the ability to decrease TGF-β1, TNF-α, PDGF and COL1A1 expression, which is highly related to prevent or remove excessive deposition of scar tissue in several organs. Basic and clinical evidence suggests that PFD may safely slow or inhibit the progressive fibrosis swelling after tissue injuries. Furthermore, a number of evidence suggests that this molecule will have positive effects in the treatment of other inflammatory diseases. This review contains current research in which PFD has been used as the treatment of several diseases, and focus mainly in the outcomes related to improve inflammation and fibrogenesis. Therefore, the main goal of this review is to focus on the novel findings of PFD efficacy rather than deepen in the chemical aspects of the molecule.
URI: 10.7150/ijms.11579
ISSN: 1449-1907
Appears in Collections:3209 Artículos

Files in This Item:
File Description SizeFormat 
Role and New Insights of Pirfenidone in Fibrotic Diseases.pdfDocumento535.69 kBAdobe PDFView/Open
Enlace a_Role and New Insights of Pirfenidone in Fibrotic Diseases.htmEnlace a publicación42.04 kBHTMLView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.